Assertio Holdings CEO Brendan O'Grady to present at iAccess Alpha Conference.
ByAinvest
Thursday, Mar 20, 2025 9:12 am ET1min read
ALPHA--
Assertio Holdings, a prominent pharmaceutical company, recently announced the appointment of Brendan P. O'Grady as its new Chief Executive Officer (CEO) [1]. With over three decades of experience in the healthcare industry, O'Grady brings a wealth of knowledge to Assertio, having previously served as CEO of the Global Formulations business at Glenmark Pharmaceuticals and Chief Commercial and Growth Officer at Amwell.
O'Grady's tenure at Teva Pharmaceuticals, where he rose to the position of CEO of Teva USA and Executive Vice President (EVP) of North America Commercial, showcases his expertise in scaling profitability, growth, and productivity. Throughout his career, he has demonstrated a strong understanding of various commercial models and a knack for market access success.
Assertio's Board of Directors expressed their delight at O'Grady's appointment, citing his exceptional leadership skills, strategic insights, and proven track record of commercial and financial execution. O'Grady, in turn, expressed his excitement about joining the Assertio team and executing the company's strategy to further diversify its asset base and drive growth.
1. Upcoming Investor Conference Presentation
Assertio Holdings' new CEO, Brendan P. O'Grady, is slated to present at the iAccess Alpha Best Ideas Spring Investment Conference on March 25-26, 2025 [2]. The presentation will take place at 1:30 pm Eastern Time (ET) on March 25. Interested investors can request one-on-one meetings with the company by contacting their conference representative or through Assertio's investor relations.
The iAccess Alpha Best Ideas Spring Investment Conference is an excellent platform for investors to engage with executives from various industries, including healthcare. Assertio's participation in the conference provides an opportunity for investors to gain insights into the company's strategy, financial performance, and growth prospects.
References:
[1] Assertio Holdings, Inc. (2024, May 29). Assertio Announces the Appointment of Brendan P. O’Grady as New CEO. Retrieved from https://www.globenewswire.com/news-release/2024/05/29/2889703/0/en/Assertio-Announces-the-Appointment-of-Brendan-P-O-Grady-as-New-CEO.html
[2] iAccess (n.d.). 2025 iAccess Alpha Best Ideas Spring Investment Conference. Retrieved from https://www.iaccess.com/events/best-ideas-spring-2025
ASRT--
O--
Assertio Holdings announced Brendan O'Grady, CEO, will present at the iAccess Alpha Best Ideas Spring Investment Conference on March 25-26, 2025. The company will present at 1:30 pm ET on March 25, and investors can request one-on-one meetings via their conference representative or through Assertio's investor relations. To register and request meetings, visit the conference website.
1. Assertio Appoints New CEO: Brendan P. O'GradyAssertio Holdings, a prominent pharmaceutical company, recently announced the appointment of Brendan P. O'Grady as its new Chief Executive Officer (CEO) [1]. With over three decades of experience in the healthcare industry, O'Grady brings a wealth of knowledge to Assertio, having previously served as CEO of the Global Formulations business at Glenmark Pharmaceuticals and Chief Commercial and Growth Officer at Amwell.
O'Grady's tenure at Teva Pharmaceuticals, where he rose to the position of CEO of Teva USA and Executive Vice President (EVP) of North America Commercial, showcases his expertise in scaling profitability, growth, and productivity. Throughout his career, he has demonstrated a strong understanding of various commercial models and a knack for market access success.
Assertio's Board of Directors expressed their delight at O'Grady's appointment, citing his exceptional leadership skills, strategic insights, and proven track record of commercial and financial execution. O'Grady, in turn, expressed his excitement about joining the Assertio team and executing the company's strategy to further diversify its asset base and drive growth.
1. Upcoming Investor Conference Presentation
Assertio Holdings' new CEO, Brendan P. O'Grady, is slated to present at the iAccess Alpha Best Ideas Spring Investment Conference on March 25-26, 2025 [2]. The presentation will take place at 1:30 pm Eastern Time (ET) on March 25. Interested investors can request one-on-one meetings with the company by contacting their conference representative or through Assertio's investor relations.
The iAccess Alpha Best Ideas Spring Investment Conference is an excellent platform for investors to engage with executives from various industries, including healthcare. Assertio's participation in the conference provides an opportunity for investors to gain insights into the company's strategy, financial performance, and growth prospects.
References:
[1] Assertio Holdings, Inc. (2024, May 29). Assertio Announces the Appointment of Brendan P. O’Grady as New CEO. Retrieved from https://www.globenewswire.com/news-release/2024/05/29/2889703/0/en/Assertio-Announces-the-Appointment-of-Brendan-P-O-Grady-as-New-CEO.html
[2] iAccess (n.d.). 2025 iAccess Alpha Best Ideas Spring Investment Conference. Retrieved from https://www.iaccess.com/events/best-ideas-spring-2025
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet